WO2013187899A1 - Compositions et procédés pour la stimulation de la cicatrisation des plaies - Google Patents

Compositions et procédés pour la stimulation de la cicatrisation des plaies Download PDF

Info

Publication number
WO2013187899A1
WO2013187899A1 PCT/US2012/042414 US2012042414W WO2013187899A1 WO 2013187899 A1 WO2013187899 A1 WO 2013187899A1 US 2012042414 W US2012042414 W US 2012042414W WO 2013187899 A1 WO2013187899 A1 WO 2013187899A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound
insulin
medium
nutrient
media
Prior art date
Application number
PCT/US2012/042414
Other languages
English (en)
Inventor
Ella Lindenbaum
Original Assignee
Ella Lindenbaum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ella Lindenbaum filed Critical Ella Lindenbaum
Priority to PCT/US2012/042414 priority Critical patent/WO2013187899A1/fr
Publication of WO2013187899A1 publication Critical patent/WO2013187899A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • compositions and methods for stimulating wound healing are provided.
  • the purpose of this invention is to improve the microenvironments in and around the wound. Specifically, it comprises of application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or its extract methyl hydroxyl chalcone polymer (MHCP).
  • tissue and cells culture nutrient media such as minimum essential media
  • insulin and/or with substances exhibiting insulin-like activity such as cinnamon or its extract methyl hydroxyl chalcone polymer (MHCP).
  • MHCP methyl hydroxyl chalcone polymer
  • Compositions according to the present invention especially compositions which include Insulin or Cinnamon or MHCP or preferably both Cinnamon or MHCP and insulin in effective amounts exhibit synergistic activity in stimulating wound healing, especially including non-healing, chronic wounds, in patients.
  • a wound is defined as a break in the continuity of the skin. It can be caused by traumatic injury such as burn, cut or scrape. A prompt treatment will avoid complications such as infection and inflammation.
  • the usual and conservative methods of closing a wound are application of various medicaments or alternatively, the wound is closed by surgical procedures of suturing the wounds edges, by grafting cultured skin or by split skin grafts. The aim of all of the above is to promote the growth of granulation tissue that may or may not follow promptly, depending on adequate blood supply bringing into the wound the nutrients that the cells need for growth.
  • the concept of this method is to use a proactive rather then protective treatment. That is, following the usage of antiseptic or anti-inflammatory medicaments, that when indicated are the standard treatments, the treatment then should be followed by induction of a stimulatory treatment.
  • the idea is to create microenvironment favorable for wound healing after assuring that the wound is clinically clean.
  • This method aims to stimulate and support growth of connective tissue components originating from the wound bed and its peripheral walls. The granulation tissue filling the wound space will create the substratum required for re- epithelialization and wound closure.
  • Wound healing or wound repair, is an intricate process in which the skin (or another organ-tissue) repairs itself after injury.
  • the epidermis the outer or superficial layer and dermis the inner or deeper layer exists in steady-state equilibrium, forming a protective barrier against the external environment. Once the protective barrier is broken, the normal (physiologic) process of wound healing is immediately set in motion.
  • the classic model of wound healing is divided into three or four sequential, yet overlapping, phases: (1) homeostatic, (2) inflammatory, (3) proliferative and (4) remodeling.
  • the proliferative phase of wound healing is characterized by angiogenesis, collagen formation and deposition, growth of granulation tissue, epithelialization, and wound contraction.
  • Angiogenesis involves formation of new blood vessels by the vascular endothelial cells. During the fibroplasia and the granulation tissue formation, the fibroblasts grow and form a new, provisional extra cellular matrix by excreting collagen and fibronectin. Concurrently, re-epithelialization of the epidermis occurs, where epithelial cells proliferate and migrate over the granulation tissue, providing cover for the new tissue.
  • Remodeling phase comprises the contraction process where the wound becomes smaller due to contraction of myofibroblasts that grip the wound edges and contract.
  • collagen is remodeled and realigned along tension lines and cells that are no longer needed are removed by apoptosis.
  • the healing is process that is not only complex but also fragile, and susceptible to interruption or failure leading to the formation of chronic non-healing wounds.
  • Factors which may contribute to this include diabetes, topical or systemic venous and/or arterial insufficiencies, old age, and infection.
  • a wound is defined as a break in the continuity of the skin. It can be caused by traumatic injury such as burn, cut or scrape. A prompt treatment will avoid complications such as infection and inflammation.
  • the usual and conservative methods of closing a wound are application of various medicaments or alternatively, the wound is closed by surgical procedures of suturing the wounds edges, by grafting cultured skin or by split skin grafts. The aim of all of the above is to promote the growth of granulation tissue that may or may not follow promptly, depending primarily on adequate blood supply that brings into the wound the nutrients that the cells need for growth.
  • the concept of this method is to use a proactive rather then protective treatment. That is, following the usage of antiseptic or anti-inflammatory medicaments, that when indicated are the standard treatments, the treatment then should be followed by induction of a stimulatory treatment.
  • the idea is to create a microenvironment favorable for wound healing after assuring that the wound is clinically clean.
  • the wound and its surrounding area will be moisturized, exposed to the rich nutrients, protected from dehydration by the gelling of the media and dressed with sterile gauze which allows the oxygen in the air to penetrate the dressing and reach the wound surface.
  • This method aims to stimulate and support growth of connective tissue components originating from the wound bed and its peripheral walls.
  • the proliferating granulation tissue filling the wound space will create the substratum required for re- epithelialization leading to wound closure.
  • This invention is based on human tissue and cell culture technology of growing fibroblast and epithelial cells in culture. Utilizing similar nutrient media supplements with insulin or alternatively with substances possessing insulin-mimetic features, the milieu in the wound becomes moist and enriched with the nutrients. These are the requirements for cells proliferation and the growth of the granulation tissue including new capillaries into the wound space.
  • Serum-free cell culture media supplemented with insulin or substances with insulin-like activity e.g. cinnamon or MHCP or MHCP and insulin-like growth factor, preferably human
  • insulin or substances with insulin-like activity e.g. cinnamon or MHCP or MHCP and insulin-like growth factor, preferably human
  • a mixture of insulin and a substance with insulin-like activity will supply the cells in the wound with the nutrients required for the process of wound healing.
  • Jarville-Taylor et. al. demonstrated the insulin-like activity was found in substances including cinnamon. They report that, in adipocytes cell cultures, Methyl Hydroxy Chalcone Polymer- (MHCP), extracted from cinnamon, acts as a mimetic of insulin. This component that is found in cinnamon affects glucose metabolism and the conversion of glucose to energy that then is utilized to enhance the cells multiplication process. In addition it renders insulin much more efficient and thus acts synergistically with insulin.
  • MHCP Methyl Hydroxy Chalcone Polymer-
  • Kamath J.V et. al. report the hydroxyproline increase in the granulation tissue content of the wound due to treatment with cinnamum zeylanicum. Anderson R. et.al recently describes the effectiveness of polyphenol type-A polymer extracted from cinnamon as a powerful insulin mimetic substance.
  • Karalee J.T. and Stapleton S.R. reported the usage of cinnamon extract to boost insulin sensitivity and that Selenium was implicated in potentiating the insulin-like activity since it stimulates glucose uptake and regulates glycolysis, gluconeogenesis and fatty acids synthesis.
  • Alt S. et al. describes using insulin and other agents to work in synergy to accelerate the healing process. However neither of them used serum-free cell culture media such as MEM, DMEM, BGJ or MCDB as a substrate.
  • Insulin has been implicates in triggering the cascade of the wound healing process.
  • Another object of this invention is to provide compositions and methods to enhance the healing of wounds and of the adjacent tissues surrounding the wound.
  • Another object is to treat the wounds by using a combination of readily available and recognizable constituents.
  • Another object is to create and support an optimal microenvironment in and around the wound thus creating a favorable optimal moisturized nutrient rich milieu for the process of wound healing.
  • Another object to a polymer delivery system is to provide compositions and methods that stimulate the cells in the wound by creating moist environment using a gelled delivery system.
  • This invention is based on human cell culture technology that grows fibroblast and epithelial cells in culture.
  • the milieu in the wound becomes moist and enriched with nutrients capable of supplying all the requirements the cells need to proliferate and grow into the wound space.
  • Preferred aspects of the invention comprise treating wounds in a cellular nutrient medium in combination with a substance possessing insulin-like activity and/or insulin.
  • the treatment of wounds may be synergistically enhanced by exposing wounds in a patient to a composition comprising an effective amount of cinnamon or MHCP or polyphenol type- A polymer and/or a non- steroidal anabolic hormone in cellular nutrient medium, optionally and preferably with an effective amount of insulin.
  • the formulation of this invention fulfills the requirements needed for promoting wound healing.
  • the formulation contains effective amounts of cellular nutrient medium such as minimum essential medium MEM or serum-free cell culture media as otherwise disclosed herein, for example, MEM, DMEM, BGJ or MCDB 153.
  • the said media is supplemented with an effective amount of insulin, a non-steroidal anabolic hormone such as insulin-like growth factor (preferably human), or alternatively by insulin-like substances such as cinnamon or its extracts (e.g. MHCP, or polyphenol type-A polymer), chromium, curcuma or selenium.
  • the preferred embodiment according to the present invention is the non-steroidal anabolic hormone is insulin.
  • the formulation also includes agents that mimic the insulin physiological activity such as cinnamon or its extracts that promote the entry of glucose into cells and converting it to energy. This energy can be utilized for regeneration of granulation tissues.
  • insulin is included in compositions according to the present invention at concentrations ranging from about 5 ng/ml (nanograms per milliliter) to about 100 ug/ml (microgram per milliliter) [corresponding to about 120 uUnits/m (micro Units per milliliter) to about 24xl0 5 uUnits/ml— approximately 0.0000005% to about 0.01% by weight], preferably about 500 ng/ml to about 500 ng/ml to about 50-10 ug/ml (about 1.2xl0 4 uUnits/ml to about 1.2xl0 5 uUnits/ml— about 0.00005% to about 0.0005% by weight of the treatment composition based upon the assumption that 1 ml of solution is equal to about t gram in weight).
  • the amount of insulin of the instant invention maybe modified according to the length of storage time prior to use.
  • compositions that are applied in solid or concentrated form i.e. as a gel, creme, lotion, elixir, powder or the like
  • the anabolic hormone is included in concentrations similar to those contained in the solutions, and preferably comprises about 0.00000005% to about 0.000005% by weight of the wound treatment composition (based upon the general assumption that 1 ml of solution is approximately equal to about 1 gram in weight of the final composition). Percent weights may fall outside of these ranges, depending upon the wound treated, the level of stability of the hormone and other factors, as well recognized by one of ordinary skill in the art.
  • spices cinnamon is water-soluble and is relatively inexpensive.
  • Cinnamon may be a substituted for insulin since it is a substance that mimic insulin physiological activity. According to Anderson et. al, it's most active derivative methyl hydroxy chalcone polymer (MHCP) function as insulin in 3T3 -L adipocytes cell cultures and was most effective in increasing glucose metabolism. Other substances such as the cinnamon derivatives MHCP or polyphenol type-A polymer, selenium, chromium, curcuma and insulin-like growth factor (especially human IGF) also known to mimic insulin activity may also be used as a substitute.
  • the biological activity of MHCP at concentrations of about 0.1 mg/ml is about equivalent to the range of activity of lOOnM of insulin.
  • Preferred MHCP concentration within the preferred media MCDB 153 ranges from about 0.01 mg/ml to about 1 mg/ml.
  • the MHCP in media ranges from about 0.025 mg/ml to about 0.5 mg/ml.
  • MHCP and insulin are combined in cellular nutrient medium to provide compositions according to the present invention.
  • insulin-like growth factor (IGF) may also be added to the present invention in effective amounts to promote wound healing, especially in chronic wounds.
  • IGF insulin-like growth factor
  • the inclusion of selenium, chromium and/or curcuma as optional insulin-like agents assists in promoting wound healing of chronic wounds according to the present invention.
  • wound is used throughout the specification to describe skin wounds, which are treated, by the formulations and the method according to the present invention.
  • a skin wound is defined herein as a breach in the continuity of the skin that is caused by direct injury to the skin.
  • Skin wounds are generally characterized by several types: punctures, incisions, including those produced by a variety of surgical procedures, excisions, lacerations, atrophic skin or necrotic wounds and burns, including large burn areas.
  • the formulation according to the present invention is used in varying degrees for enhancing the healing of all types of wounds of the skin, including those which occur after a mesh autograph procedure. Compositions according to the present invention are unexpectedly effective to treat chronic wound conditions.
  • delivery polymer is used throughout the specification to describe a polymer which can be used in combination with a cellular nutrient medium (preferably, serum free), a non-steroidal anabolic hormone insulin or insulin-like substances and mixtures thereof, and optionally, individually which are preferably used for topical application to the treated wounds according to the present invention.
  • a cellular nutrient medium preferably, serum free
  • non-steroidal anabolic hormone insulin or insulin-like substances and mixtures thereof preferably used for topical application to the treated wounds according to the present invention.
  • These delivery systems polymers include, for example, numerous hydrogels in hydrated or unhydrated form, such as those derived from hydroxyethylmetacrylate (HEMA), glycerolmetacrylate (GMA) and polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and various carbohydrates, cellulose, and related hydrophilic cellulose polymers, dextran, polyethyleneoxide, dextran-polyethylene, acrylamide, amylase, collagen, gelatin, sepharose, agarose (for example, as an agarose saturated gel), related polymers and mixtures thereof, among numerous others.
  • HEMA hydroxyethylmetacrylate
  • GMA glycerolmetacrylate
  • PVP polyvinylpyrrolidone
  • PEG polyethylene glycol
  • various carbohydrates cellulose, and related hydrophilic cellulose polymers, dextran, polyethyleneoxide, dextran-polyethylene, acrylamide, amylase, collagen, gelatin, sepharose, agarose (
  • delivery polymer is also used to describe polymers that provide slow-release or sustained release characteristics to the wound healing formulations of the invention.
  • gelling agent is used to describe those polymers, which may be included in aqueous formulations according to the present invention in effective amounts to gel these formulations.
  • MHCP methyl hydroxy chalcone polymer
  • Compositions which include effective amounts of MHCP and insulin and optionally, at least one further component selected from the group consisting of insulin-like growth factor (IFG), polyphenol type-A polymer, selenium, chromium, curcuma and mixtures thereof are preferred aspects of the invention because of the synergistic favorable impact such components have on wound healing, especially the healing of chronic wounds.
  • IGF insulin-like growth factor
  • polyphenol type-A polymer polyphenol type-A polymer
  • selenium chromium, curcuma and mixtures thereof
  • MHCP is included in compositions according to the present invention in an effective amount, generally at concentration ranging from about O.OOlmg/ml to about 25 mg/ml, about 0.01 mg/ml to about 10 mg/ml, about 0.025 mg/ml to about 5 mg/ml, although concentrations outside of these ranges are . also useful.
  • the MHCP ranges from about 0.025 mg/ml to about 0.5-1.0 mg/ml.
  • the biological of activity of 0.1 mg/ml of MHCP is approximately equivalent to the biological activity of aboutlOO nM of insulin. Percentage weights may fall outside of these ranges, depending upon the type and size of the wound and other factors, as well recognized by one of ordinary skill in the art.
  • the biological activity of MHCP at concentrations of about 0.1 mg/ml is about equivalent to the range of activity of lOOnM of insulin.
  • Preferred MHCP concentration within the preferred media MCDB 153 ranges from about 0.01 mg/ml to about 1 mg/ml.
  • Preferably the MHCP in MCDB 153 ranges from about 0.025 mg/ml to about 0.5 mg/ml.
  • polyphenol type- A polymers found in cinnamon may function as antioxidants, and act as synergistic agents to insulin by potentiating its action and by also contributing to the control of glucose tolerance and diabetes.
  • cellular nutrient medium or “cellular nutrient mixture” is used throughout the specification to describe a medium or mixture (generally, at least a minimum essential medium) which preferably contains no serum (is serum-free), and in combination with insulin or insulin-like substances (e.g. MHCP, polyphenolic type-A polymer, insulin-like growth factor, selenium, chromium, curcuma and mixtures thereof), at least one of them comprising the wound healing compositions according to the present invention.
  • insulin or insulin-like substances e.g. MHCP, polyphenolic type-A polymer, insulin-like growth factor, selenium, chromium, curcuma and mixtures thereof
  • the nutrient medium preferably serum-free, according to the present invention comprises the following elements: (a) essential amino acids; (b) non-essential amino acids; (c) vitamins selected from a group consisting of biotin, folate, lipoate, niacinamide, pantothenate, pyrodine, riboflavin, thiamin and vitamin Bj 2 and mixtures thereof, preferably a vitamin mixture comprising folate, niacinamide, pantothenate, pyrodine, riboflavin and thiamin; (d) glucose; and (e) a mixture of inorganic ions selected from a group consisting of calcium, sodium, potassium, magnesium, chloride and mixtures thereof, preferably a mixture comprising calcium, potassium, magnesium and chloride.
  • All of these elements (a), (b), (c), (d) and (e) are included with the anabolic hormone and optionally the insulin like substances in concentrations and/or amounts effective for enhancing the growth of cells which surround, have been injured by or are responsible for healing a wound.
  • the preferred concentration of essential and non-essential amino acids used in the present invention is from about 5.0 um (!0 "6 mole) to about 50 mmol. (10 "3 mole).
  • the proffered concentration of vitamins used in the present invention ranges from about 1 nanomole (10 "9 mol.) to about 10 um.
  • the preferred concentration of glucose used in this invention ranges from about 1 umol. to about 10 or more mmol.
  • these organic ions are preferably included in the present compositions are at concentration ranges of about 1 umol to about 50 mmol.
  • the nutrient medium according to the present invention optionally contain any one of one or more of the following element: (f) purines and pyrimidines; (g) other organic compounds; (h) other inorganic ions; (i) trace elements; (j) buffers and indicators and (k) other supplements.
  • All of the optional elements (f), (g), (h), (i), (j) and (k), when they are included in the nutrient medium according to the present invention are included in the amounts effective for enhancing the growth of cells involved in wound healing processes in combination with insulin or its mimicking substitute cinnamon or MHCP, further including an effective amount of insulin-like growth factor, IGF, selenium, chromium, curcuma and mixtures thereof.
  • components (f), (g), (j) and (k) range in concentration from about 1 mmol to about 10 mmol. In the case of components (h) and (j) the concentration preferably ranges from about 1 umol. to about 50 mmol.
  • concentration preferably ranges from about 1 umol. to about 50 mmol.
  • the present invention may also make use of cellular nutrient medium containing serum, although the use of serum containing cellular nutrient medium is generally less preferred than is serum free medium.
  • examples of such nutrient medium include, among numerous others, DMEM, HAM F12 and HAM F10, all containing serum.
  • cellular nutrient medium or "nutrient mixture” is used to describe all types of nutrient medium contemplated for the use in the present invenion which contain at least the basic elements (generally, of a minimum essential medium) as described hereinabove, and such term includes serum free cellular nutrient medium.
  • the cellular nutrient medium according to the present invention includes one or more commercially available media in solution or lyophilate (solid) form.
  • the cellular nutrien medium used may be in the form of a lyophilate which may be reconstructed with water, preferably sterilized, distilled water and then supplemented with the anabolic hormone insulin or cinnamon or hydroxychalcone or polyphenol type-A polymer or mixtures thereof, and optionally, by each one separately and further including optional components IGF, selenium, chromium or curcuma and mixtures thereof.
  • the nutrient medium may be used directly in formulations according to the present invention in the form of a lyophilate, or related solid-type material, rather than a solution, especially when gels, creams, elixirs, powders or other delivery vehicles are to be used for delivery. It is clearly preferred when utilizing solid-type materials for delivering the wound healing compositions according to the present invention that the delivery system in the form of a hydrogel or other form containing moistening quantities of water.
  • non-steroidal anabolic hormone is used throughout the specification to describe the primary hormone in the instant invention that promotes wound healing in combination with cellular nutrient media.
  • the primary hormone is insulin or alternatively a nutrient substitute such as cinnamon, or other natural product which contains effective amounts of MHCP itself or polyphenol type-A polymer.
  • nonsteroidal anabolic hormone includes naturally isolated (preferably human) or synthetically produced versions of insulin that are known to function substantially the same as the naturally occurring hormone and includes, where relevant, compounds produced by genetic
  • the non-steroidal anabolic hormone that is especially preferred is insulin. While not being limited by way of theory, it is believed that the inclusion of at least one selected from the two, insulin or MHCP and preferably both components, serves to enhance the effect of the nutrient media in increasing the rate and natural process of wound healing. Thus, it is believed that the non-steroidal anabolic hormone actually enables the wound cells to utilize or process the nutrient in the media, which action result in an enhanced rate of wound healing.
  • a combination of insulin and MCHP in effective amounts as otherwise described herein is shown to be synergistic in enhancing wound healing.
  • each component which is used in the formulation according to the present invention, will depend upon the type and size of the wound, but each component preferably is included in the amount effective for significantly enhancing the healing of a wound relative to traditionally wound healing therapies.
  • the formulation include an anabolic hormone or similar agent such as IGF and/or insulin in concentrations of at least about 0.005 ng/ml preferably about 0.5 ng/ml to about 50 ng/ml or more, more preferably about 50 ng/ml to about 20 ng/ml or more.
  • the amount of insulin generally falls outside of this range, because of its tendency to degrade and become inactive a more rapid rate then other anabolic hormones.
  • the anabolic hormone is insulin and/or a cinnamon extract as insulin substitute such as methylhydroxychalcone polymer or polyphenol type-A polymer, further including one or more of selenium, insulin-like growth factor, chromium, curcuma and mixtures thereof and because of the benefit this hormone or its substitute(s) have in promoting the growth and elaboration of cells and their generally absence of toxicity.
  • the preferred anabolic hormone is human insulin, which is well-known protein is readily commercially from a number of sources (for example, Sigma Chemical Co., USA or Novo Nordisk, Copenhagen, Denmark). It is constituted from a number of amino acids (approximately 51) with a total molecular weight of about 5,500. Human insulin for use in the present invention is generally prepared using genetic engineering techniques.
  • the insulin may have slightly different activity based upon its weight; however the activity of insulin defined in units is, of course, standard. While not being limited by way of theory, in the present invention, it is believed that the insulin promotes the wound healing by enhancing the transport and utilization of glucose by the cells.
  • the cellular nutrient medium used in the present invention, is any nutrient medium having the effect of enhancing the recovery of wounded or atrophic skin tissues when used in combination with the cell growth-stimulating compound.
  • the nutrient media is composed of the components set forth herein, it is mixed with effective amounts of the non-steroidal anabolic hormone or its substitute to form the compositions of the present invention.
  • the medium is serum-free.
  • the cellular media comprises effective amounts of the following constituent: (a) essential; (b) non-essential amino acids; (c) vitamins as previously decribed; (d) inorganic ions as previously described and (e) glucose; optionally, (f) purines and pyrimidines; (g) other organic compounds; (h) other inorganic ions; (i) trace elements; (j) buffers and indicators and (k) other supplements.
  • the cellular nutrient medium used herein contains effective amounts of elements (f) through (k).
  • Serum free nutrient medium is preferred.
  • the preferred serum free nutrient medium is modified MCDB, a well-known medium. Mixtures of standard nutrient media may also be used with favorable results in the instant invention.
  • the presence of the anabolic hormone, and in particular, insulin and/or hydroxychalcone (preferably a mixture of at least one of these and most preferably a combination of insulin and MHCP in nutrient medium, further including IGF, cinnamon, selenium, chromium and/or curcuma) in the formulations according to the present invention promotes the utilization of the nutrient medium and consequentially, growth in situ of the granulation tissue, i.e., within the wound itself.
  • the novel formulations may also induce the stimulation of the vascular elements and promote the growth of vascularized granulation tissue preparatory to split skin grafting.
  • the present formulation may in this same way also be useful to promote the healing, growth and regeneration of atrophic skin and to function as atrophic skin adjuvants.
  • the proliferation of vascularized granulation promotes epidermal growth from the peripheral edges of the wound over the vascular granulation tissue substratum and from the deeper layers of the dermis leading to an early closure of the skin over the wound.
  • the mechanism which might be assumed, is that in the proliferation phase, new capillaries and fibroblasts appear in the wound from the first day on and reach their maximum levels after one week.
  • the new vessels in the granulation tissue originate as budlike structures on nearby vessels, penetrating the wound, become canalized and ramify throughout the wound by cell multiplication.
  • the function of the nutrient medium is to provide nutrients to the normal, distressed and injured cells and skin that surround or comprise the wound to be treated, in order to enhance the growth and repair mechanisms that are responsible for the healing of the wound.
  • the nutrient medium functions with the anabolic hormone or the nutrient substitute to promote the normal processes of elaboration, synthesis and growth leading to the healing of the wound and adjacent skin areas.
  • the gelled media serves to maintain a moist environment surrounding the wound area.
  • a number of nutrient media, preferably serum free, alone or in combination may be used in the present invention, including commercially available media or other media well known in the art.
  • examples of such media include ADC-1, LPM (BOVINE Serum albumin-free), (10 (HAM), F12 (HAM), DCCM1, DCCM2, RPMI 1640, BGJ Medium (Fitton- Jackson Modification), Basal Medium Eagle (BME with the addition of Earl's salt base), Dulbecco's Modified Eagle Medium (DMEM- without serum), Glasgow Modification Eagle Medium (GMEM), Leibovitz L-15 Medium, McCoy's 5 A medium, Medium Ml 99 (M199E-with Eagle's Minimum Essential Medium (MEM-E with Eagle base), Minimum Essential Medium Eagle (MEM-H-with Hank's salt base) and Minimum Essential Medium Eagle )MEM-NAA-with non essential amino acids), among numerous others.
  • These and other useful serum-free nutrient media are available from GIBCO, Grand
  • serum-containing nutrient media may also be used in compositions according to the present invention, but the use of the serum-containing media is less preferred because of the possibility that the serum may be contaminated with microbial agents and because the patient may develop immunological reaction to certain antigenic components contained in the serum.
  • a preferred but not the only nutrient media for use in the present invention is modified MCDB 153.
  • Weights of each of the above in the medium may be varied within the concentration described herein above, to provide formulations workable within the description of the present invention.
  • the non-steroidal anabolic hormone to be incorporated into the MCDB 153 composition according to the present invention is a mixture of insulin and/or its substitute at effective concentrations.
  • the anabolic hormone insulin (with or without transferring) or the insulin substitute each included in effective concentrations for promoting wound healing.
  • the effective amount of insulin generally ranges from about 5 ng/ml to about lOOug/ml and more preferably about 500ng/ml to about 5ug/ml within this range. Higher amounts of insulin may be merited where the formulation is stored for longer periods of time.
  • the synergistic activity of insulin and its nutrient substitute suggests that they will enhance the activity of the indigenous natural occurring insulin in and around the wound whether the wound is traumatic or results from atrophic processes and the concomitant sparse blood supply to the area.
  • the anabolic hormone insulin was found to impart a maturing stimulus of the growing culture.
  • Insulin may be commercially obtained and generally provided in mil quantities (about 41 ng of insulin).
  • the Standard Preparation is quantity of purified Zinc Insulin crystals extracted 52% from Bovine and 48% from Porcine pancreas (se Martindale Pharmacopoeia, 26 th Ed.).
  • the formulation according to the present invention may also include an effective amount of an antimicrobial agent, for example, antiseptic, antibiotics, antiviral and antifungal agents, such as griseofulvin and nystatin, and the like.
  • an antimicrobial agent for example, antiseptic, antibiotics, antiviral and antifungal agents, such as griseofulvin and nystatin, and the like.
  • the antimicrobial agent may be added for its ability to treat infections, or alternatively, for its prophylactic effect avoiding an infection.
  • an amount effective to treat an infection or a prophylactic amount of such agents is chosen.
  • the amount of antimicrobial agent used is that amount typically used in topical application.
  • One of ordinary skill in the art can easily determine the type and amount of antimicrobial agents chosen for use in formulations according to the present invention.
  • the antimicrobial agent may vary widely depending on the efficacy of the agent to be delivered and the prophylactic treatment or the severity of the infection.
  • the amount of antimicrobial agent to be used in the present invention will range from about 0.05 ug/ml to about 250 mg/ml with the preferred range of about 50 to about 200 ug/ml.
  • these ranges will vary depending upon the condition of the infection to be treated as well as the strength of the antimicrobial agent employed.
  • the amount of amphotericin used generally ranges from about 0.1 ug/ml to about 100 ug/ml with a preferred concentration of about 0.25 ug/ml.
  • antibiotics and in particular, penicillin, streptomycin and gentamycin
  • these agents are generally utilized within the concentration range of about 0.05 ug/ml to about 250 mg/ml with preferred concentration of about 25ug/ml to about 250 ug/ml.
  • antibiotics any number of antibiotics may be used, including sulfa drugs, penicillin, chloramphenicol and aminoglycosides, among others, but it is preferable to use the broad spectrum antibiotics, for example cephalosporin or tetracycline in a prophylactic amount or alternatively, in an amount effective for treating bacterial infection.
  • broad spectrum antibiotics for example cephalosporin or tetracycline in a prophylactic amount or alternatively, in an amount effective for treating bacterial infection.
  • antibiotics one of ordinary skill in the art will recognize to minimize or avoid the use of antibiotics that may produce allergic reactions in the treated patients.
  • the formulations as described herein are further formulated with hydrogels or related delivery polymers for delivering the formulation according to the present invention to the wound.
  • the formulations consists of effective amounts of anabolic hormone insulin or it nutrient substitute with a nutrient media, either alone or in addition to other optional components, are admixed with amounts of a delivery polymer effective for producing a gel, for example a hydrogel polymer derived from HEMA (Hydroxyethylmethacrylate) or NVP (N-vinylpyrrlidone), polyethylene glycol (PEG), polyethylene, gelatin, various carbohydrates, sepharose, agarose, methylcellulose, hydroxymethyl and hydroxyethylcelluloseand related hydrophilic cellulose polymers including cellulose, dextran, polyethylene oxide, dextrin- polyethylene, agarose, acrylamide, polyacrilamide, amyloseor collagen to promote wound healing and skin growth.
  • HEMA Hydrogel polymer derived from HEMA (Hydroxyeth
  • the amount of delivery polymer which is added to the formulations produce a gel generally ranges from about 0.1% by weight to about 20% by weight, preferably about 1% to about 5%or more by weight, depending upon the type of delivery polymer used.
  • the gel compositions according to the present invention preferably contain sufficient water or moisture to maintain the wound environment in a moist state - a condition shown to be beneficial to the wound healing.
  • the compositions that are formulated with a delivery polymer also exhibit the added .benefit of preventing or slowing the formation of a scab on the wound. While not being limited by way of theory, it is believed that the resultant wound tissue, which remains soft and moist instead of dry and scab-like, produces a beneficial, cosmetically pleasing and increased rate wound healing.
  • compositions according to the present invention also may be formulated as creams, elixirs, lotions, powders and the like.
  • the various components of the wound treatment compositions according to the present invention may have to be varied in order to maintain effective concentrations for promoting wound healing.
  • these compositions may also contain an amount of pharmaceutically acceptable excipient and, in addition, other additive such as diluents, compounding agents, bulking agents, surfactants and the like.
  • concentrations of the individual components as a function of the type of delivery vehicle used for the wound treatment compositions in order to facilitate and enhance the wound healing activity of the present formulations.
  • the formulations as described hereinabove are topically applied to the wound tissue as a liquid or gel preferably at least once a day and up to six or more times a day.
  • the formulations may be administered less frequently then when the formulation are applied as a liquid, for example, once every several days or more.
  • a delivery polymer preferably as a moisten delivery polymer
  • the formulations may be administered less frequently then when the formulation are applied as a liquid, for example, once every several days or more.
  • One of ordinary skill in the art will readily be able to determine the amount and frequency of administering the formulation according to the present invention.
  • the amount of material that is spread on the wound as a treatment will be readily apparent to one of ordinary skill in the art.
  • about lcc of the formulation is applied per 1 cm 2 of the wound area.
  • an amount greater or lesser then the lcc of formulation per 1 cm 2 of the wound surface may be utilized.
  • the depth of the formulation on the wound shall be at least about 2 mm and shall cover the whole surface of the wound.
  • the preferred media contained essential and non-essential amino acids, Vitamins, other organic constituents, major inorganic salts, trace elements and buffers are supplemented with CaCl, L-glutamine and the non-steroidal anabolic hormone insulin. At concentrations indicated below.
  • Folic Acid 1.8 x lO "6 DL-a-lipoic acid 1.0 X 10 "6 Niacinamide 3.0 x lO- 7 D-panto thenate l/20a 1.0 x lO "6 Pyridoxine HC1 3.0 x lO "7 Riboflavin 1.0 x 10 "7 Thiamin HC1 1.0 x 10 "6 Vitamin B 12 3.0 x lO "7
  • Insulin-like MHCP 0.5 mg/ml
  • EEO electro endosmosis 0/10-0.15
  • Hartley-derived albino guinea pigs weighing 300-400 grams were used in this study.
  • the animals were housed in individual cages and fed regularly guinea pig chow and water enriched with Oitamin C ad libitum. All Surgical procedures were performed under general anesthesia using Katamin HC1 ([d]-2-(o-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride, available from Park-Davis) 150 mg/kg i.m. All histological sections were prepared using hematoxylene and Eosin stain as well as Mason's trichrome method for collagen.
  • Each animal was anesthetized and four bilateral symmetrical full thickness skin segments measuring 2x3 cm were excised from the dorsum of each animal, two from the scapular region and two from the lumbar region. After washing the wound with warm saline, the wounds were dressed with the gel at a concentration of about 1 cc/cm , covered with a polyethylene base synthetic membrane Omiderm (Omicron, Israel) and anchored with gauze, elastic adhesive and Retelast netting (Medinet, s.p.a., Italy).
  • the dressing were changed every 48 hours under general anesthesia, at which time the wounds were washed with warm saline to remove any debris and the remaining gel within the wound, measures, photographed and fresh gel was applied and the wounds dressed as described above.
  • days 4, 6, 8, 10, and 12 the animals were sacrificed and the wounds with the surrounding structures were removed and prepared for histological examination.
  • the thickness of the newly formed epithelial layer and the underlying granulation tissue were measured using light microscopy (Zeiss) at lOOx magnification.
  • the wound micrographs were analyzed using ImageMeasure (Phoenix Corp., Seattle, Wash.) computerized morphometric program and the experimental results were plotted as graphs showing the fractional change in the area (i.e. the closure rate) of the wounds treated with the gel-media + hormone versus the various controls.
  • the wound closure rate was tabulated and peak closure day (% closure) was determined.
  • Peak closure rate has been used as the measure of wound healing potency. Peak closure rate is the maximum slope of the Vs, time curve.
  • Peak closure rate indicate the time after the start of the treatment at which tissue healing or growth rate reaches a maximum value (Maximum rate); i.e. when the treatment is optimal. Seven groups of experiments were performed using various combinations of medicaments as controls:
  • Gelatin and Agarose were prepared in saline and the two gels were used to treat experimental wounds.
  • the rate of closure of the wounds treated with Agarose was faster than the rate of closure of wounds treated with gelatin.
  • Wound closure comparison indicates that the closure of 50% was 31% faster with Agarose in saline as compared to Gelatin in Saline. Peak closure rate occurred 33% earlier with Agarose in Saline treatment.
  • Scarlet red dressing (O-Tolylazo-oTolylazi-beta-naphthol plus lanolin, olive oil and petroleum from Chesebrough-Ponds, Inc., hospital Products Division, Greenwich, Conn., USA-an azo dye-containing preparation routinely used in hospitals and claimed to increase epithelialization) was used as a positive control and saline in Agarose was used as negative control.
  • Treatment with media + insulin formulation induced accelerated wound healing compared to treatment with media prepared in Agarose without insulin.
  • the rate of wound closure using the media alone was similar to that of the wound treated with saline in Agarose.
  • the rate of wound closure with the media + disinfectant treatment was initially faster than that of the wounds treated with media alone. However, on the 2 nd day the rate of the wound closure for wounds treated with media + insulin accelerated and was faster than the closure rate of wounds treated with the addition of the disinfectant compress. After the initial period of time, the disinfectant exerted cumulative cytotoxic effect that slows the healing process.
  • Scarlet red dressing as a positive control and Saline as a negative control yielded similar results and slower closure when compared with media + Insulin treatment.
  • wounds are clean, surgically made and uncomplicated by contamination. This point is important since the gel media may provide a growth substrate for bacteria. It is believed that, in contaminated wounds, a bacteriogram followed by or concomitant with specific antibiotics or disinfectant treatment in combination with the gel media treatment may be indicated.
  • moist dressing is used to create optimal environment and to prevent desiccation of the wound bed.
  • Enriched cell culture medium supplemented with insulin was gelled in 1% agarose. The gel was applied to the surface of the wound (lml/cm ) once a day. All wound included in the study were clinically clear of infection, following topical antiseptics or antibiotics. Etiology of the wounds was varied from venous and/or arterial insufficiency to insulin-dependant and non- dependant diabetic ulcers, or combinations of the above.
  • An 80-year-old male was a non-insulin-dependant patient. He suffered from venous insufficiency, asthma controlled by prednisone, and from siderblastic anemia. He presented with a two years old leg ulcer which previously was treated with antiseptics. The treatment with the gel lasted 4 months partially in the hospital and later on an ambulatory basis.
  • the gel treatment aims to change microenvironment of the chronic atrophic wound thereby affecting the metabolic processes in the wound cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant d'améliorer les microenvironnements dans et autour de la plaie dans un effort pour favoriser la cicatrisation. Spécifiquement, la présente invention concerne l'application d'un milieu de culture nutritif de tissus et cellules, comme un milieu essentiel minimum, complété avec de l'insuline et/ou avec des substances présentant une activité de type insulinique, comme la cannelle ou des extraits de cannelle, notamment entre autres MHCP. Le milieu est appliqué sur la plaie pour stimuler les cellules viables dans le lit de la plaie et les cellules adjacentes dans la périphérie de la plaie pour qu'elles prolifèrent et croissent dans la plaie pour aboutir à la fermeture de la plaie.
PCT/US2012/042414 2012-06-14 2012-06-14 Compositions et procédés pour la stimulation de la cicatrisation des plaies WO2013187899A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042414 WO2013187899A1 (fr) 2012-06-14 2012-06-14 Compositions et procédés pour la stimulation de la cicatrisation des plaies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042414 WO2013187899A1 (fr) 2012-06-14 2012-06-14 Compositions et procédés pour la stimulation de la cicatrisation des plaies

Publications (1)

Publication Number Publication Date
WO2013187899A1 true WO2013187899A1 (fr) 2013-12-19

Family

ID=49758571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/042414 WO2013187899A1 (fr) 2012-06-14 2012-06-14 Compositions et procédés pour la stimulation de la cicatrisation des plaies

Country Status (1)

Country Link
WO (1) WO2013187899A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461030A (en) * 1991-02-01 1995-10-24 Life Medical Science, Inc. Compositions and methods for enhancing wound healing
US20020122787A1 (en) * 2000-04-06 2002-09-05 Newell Martha K. Compositions and methods for promoting wound healing
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461030A (en) * 1991-02-01 1995-10-24 Life Medical Science, Inc. Compositions and methods for enhancing wound healing
US20020122787A1 (en) * 2000-04-06 2002-09-05 Newell Martha K. Compositions and methods for promoting wound healing
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAMATH, J. V. ET AL.: "Pro-healing effect of Cinnamomum zeylanicum Bark", PHYTOTHERAPY RESEARCH, vol. 17, no. ISSUE, 2003, pages 970 - 972 *

Similar Documents

Publication Publication Date Title
US5591709A (en) Compositions and methods for treating wounds
AU670413B2 (en) Compositions and methods for treating wounds
JP5869219B2 (ja) 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
US20090325861A1 (en) Dry wound dressing and drug delivery system
Dart et al. Topical treatments in equine wound management
CN105107007A (zh) 一种阳离子医用护创敷料及其制备方法
KR101367340B1 (ko) 아미노산 및 히알루론산 나트륨에 기반한 멸균 분말 제형의상처-치료용 약학적 조성물
US10292997B2 (en) Compositions and methods for stimulating wound healing
RU2522214C1 (ru) Способ стимуляции заживления ран различного генеза природным антиоксидантом дигидрокверцетином
WO2013187899A1 (fr) Compositions et procédés pour la stimulation de la cicatrisation des plaies
KR20200044434A (ko) 물질 p를 포함하는 난치성 궤양 치료용 조성물
WO2012095702A1 (fr) Composition pour régénérer des tissus atrophiques
US10232004B2 (en) Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers
RU2577950C1 (ru) Способ стимуляции заживления дермальных ожогов
Jain et al. Effect of moist dressing, collagen sheet dressing and epidermal growth factor in healing of chronic wounds
RU2369398C2 (ru) Средство с ранозаживляющей активностью на основе супернатанта человеческих фибробластов
EP3000475B1 (fr) Composition pharmaceutique ou cosmétique pour la régénération et la cicatrisation de la peau
RU2278689C2 (ru) Способ лечения трофических язв и длительно незаживающих гнойных ран
Enderami et al. Applications of blood plasma derivatives for cutaneous wound healing: A mini-review of clinical studies
RU2552336C1 (ru) Средство для лечения гнойных ран, гнойных полостей и трофических язв
CA3168280A1 (fr) Composition de cicatrisation de plaies chroniques et son application
AU2021394748A9 (en) Compositions and methods for treating wounds
RU41613U1 (ru) Устройство для лечения трофических язв и длительно заживающих гнойных ран
Stashak et al. Topical wound treatments
WO2002064178A1 (fr) Utilisation d'extrait de the vert pour soigner des plaies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12878695

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12878695

Country of ref document: EP

Kind code of ref document: A1